Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial

References

• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55); 2020 Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. The American Psychiatric Association; 2013. doi:10.1176/appi.books.9780890425596
   Google Scholar
• Center for Disease Control and Prevention. Wide-ranging online data for epidemiologic research (WONDER); 2020. Atlanta, GA: CDC, National Center for Health Statistics. http://wonder.cdc.gov.
   Google Scholar
• National Institute on Drug Abuse. Principles of drug addiction treatment: a research-based guide. 3rd ed. Rockville, MD: National Institute on Drug Abuse; 2012. NIH Publication No. 12-4180. www.drugabuse.gov/publications/principles-drug-addiction-treatment
   Google Scholar
• Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58:85–92. doi:10.1016/S0376-8716(99)00063-0.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97–100. doi:10.1016/S0140-6736(96)90215-9.
   PubMed Web of Science ®Google Scholar
• Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1:13–20. doi:10.1151/spp021113.
   PubMedGoogle Scholar
• Tetrault JM, O’Connor PG. Management of opioid intoxication and withdrawal. In: Ries RK, DA Fiellin, SC Miller R Siatz, editors. Principles of addiction medicine. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. pp. 589–606.
   Google Scholar
• Gold MS, Redmond DE Jr., Kleber HD. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry. 1979;136:100–02.
   PubMed Web of Science ®Google Scholar
• Gossop M. The development of a short opiate withdrawal scale (SOWS). Addict Behav. 1990;15:487–90. doi:10.1016/0306-4603(90)90036-W.
   PubMed Web of Science ®Google Scholar
• Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev. 1997;21:91–104. doi:10.1016/0149-7634(95)00061-5.
   PubMed Web of Science ®Google Scholar
• Doughty B, Morgenson D, Brooks T. Lofexidine: a newly FDA-approved, Nonopioid treatment for opioid withdrawal. Ann Pharmacother. 2019;53:746–53. doi:10.1177/1060028019828954.
   PubMed Web of Science ®Google Scholar
• Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, Biswas KA. Phase III, randomized, multi-center, double blind, placebo-controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176:79–88. doi:10.1016/j.drugalcdep.2017.02.020.
   PubMed Web of Science ®Google Scholar
• Kuszmaul AK, Palmer EC, Frederick EK. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. J Am Pharm Assoc. 2003;60:145–52. doi:10.1016/j.japh.2019.10.004.
   Google Scholar
• Strang J, Bearn J, Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict. 1999;8:337–48. doi:10.1080/105504999305749.
   PubMed Web of Science ®Google Scholar
• Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, Delsignore R. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001;21:11–17. doi:10.1016/S0740-5472(01)00178-7.
   PubMed Web of Science ®Google Scholar
• Jones JD, Varshneya NB, Hudzik TJ, Huhn AS. Improving translational research outcomes for opioid use disorder treatments. Cur Addict Rep. 2021;8:109–21. doi:10.1007/s40429-020-00353-5.
   PubMedGoogle Scholar
• Lopez LM, Mehta JL. Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension. Am J Cardiol. 1984;53:787–90. doi:10.1016/0002-9149(84)90405-3.
   PubMed Web of Science ®Google Scholar
• Hsu YW, Cortinez LI, Robertson KM, Keifer J, Sum-Ping S, Moretti E, Young C, Wright D, MacLeod D, Somma J. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004;101:1066–76. doi:10.1097/00000542-200411000-00005.
   PubMed Web of Science ®Google Scholar
• Kamibayashi T, Maze M, Weiskopf R, Weiskopf R, Todd M. Clinical uses of α2-adrenergic agonists. Anesthesiol. 2000;93:1345–49. doi:10.1097/00000542-200011000-00030.
   PubMed Web of Science ®Google Scholar
• Kaur M, Singh PM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res. 2011;5:128–33. doi:10.4103/0259-1162.94750.
   PubMedGoogle Scholar
• IGALMITM. Package insert. BioXcel Therapeutics, Inc.; 2022.
   Google Scholar
• Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc Bayl Univ Med Cent. 2001;14:13–21. doi:10.1080/08998280.2001.11927725.
   PubMedGoogle Scholar
• Peltonen JM, Pihlavisto M, Scheinin M. Subtype-specific stimulation of [35S] GTPgammaS binding by recombinant alpha2-adrenoceptors. Eur J Pharmacol. 1998;355:275–79. doi:10.1016/S0014-2999(98)00518-4.
   PubMed Web of Science ®Google Scholar
• Ouchi K, Sugiyama K. Dexmedetomidine dose dependently enhances the local anesthetic action of lidocaine in inferior alveolar nerve block: a randomized double-blind study. Reg Anesth Pain Med. 2016;41:348–55. doi:10.1097/AAP.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bai X, Zhang Q, Wang X, Lu L. The safety and efficacy of intranasal dexmedetomidine during electrochemotherapy for facial vascular malformation: a double-blind, randomized clinical trial. J Oral Maxillofac Surg. 2013;71:1835–42. doi:10.1016/j.joms.2013.06.202.
   PubMed Web of Science ®Google Scholar
• Penttilä J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of dexmedetomidine in healthy subjects. Can J Physiol Pharmacol. 2004;82:359–62. doi:10.1139/y04-028.
   PubMed Web of Science ®Google Scholar
• Wagner DS, Brummett CM. Dexmedetomidine: as safe as safe can be. Sem Anesthesia Perioperative Med Pain. 2006;25:77–83. doi:10.1053/j.sane.2006.02.003.
   Google Scholar
• Sobell LC, Sobell MB, Buchan G, Cleland PA, Fedoroff I, Leo GI. The reliability of the timeline followback method applied to drug, cigarette, and cannabis use. Paper presented at the 30th Annual Meeting of the Association for Advancement of Behavior Therapy; 1996 Nov; New York, NY.
   Google Scholar
• Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, et al. The Columbia–suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–77. doi:10.1176/appi.ajp.2011.10111704.
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35:253–59. doi:10.1080/02791072.2003.10400007.
   PubMed Web of Science ®Google Scholar
• Wang RI, Wiesen RL, Lamid S, Roh BL. Rating the presence and severity of opiate dependence. Clin Pharmacol Ther. 1974;16:653–58. doi:10.1002/cpt1974164653.
   PubMed Web of Science ®Google Scholar
• Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F, et al. A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend. 2008;97:158–68. doi:10.1016/j.drugalcdep.2008.04.002.
   PubMed Web of Science ®Google Scholar
• Battaglia J, Lindborg SR, Alaka J, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emergency Med. 2003;21:192–98. doi:10.1016/S0735-6757(02)42249-8.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Risinger R, Kakar R. Sublingual dexmedetomidine vs placebo and acute agitation associated with bipolar disorder-reply. JAMA. 2022;328:214–15. doi:10.1001/jama.2022.8349.
   PubMed Web of Science ®Google Scholar
• Precedex US Package Insert; 2016. http://labeling.pfizer.com/ShowLabeling.aspx?id=4404
   Google Scholar
• Comer SD, Collins ED, MacArthur RB, Fischman MW. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology (Berl). 1999;143:327–38. doi:10.1007/s002130050956.
   PubMed Web of Science ®Google Scholar
• Comer SD, Cooper ZD, Kowalczyk WJ, Sullivan MA, Evans SM, Bisaga AM, Vosburg SK. Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. Psychopharmacology (Berl). 2010;208:45–55. doi:10.1007/s00213-009-1703-4.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33:1179–91. doi:10.1038/sj.npp.1301479.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, et al. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol. 2016;21:895–903. doi:10.1111/adb.12261.
   PubMed Web of Science ®Google Scholar
• SAS Proprietary Software Version 9.3. Cary NC: SAS Institute.
   Google Scholar
• Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth. 2011;107:430–37. doi:10.1093/bja/aer164.
   PubMed Web of Science ®Google Scholar
• Hospira. Approved labeling for precedex (dexmedetomidine hydrochloride) injection for intravenous use. Lake Forest, IL: Hospira, Inc; 2016.
   Google Scholar
• Kundra P, Velayudhan S, Krishnamachari S, Gupta SL. Oral ketamine and dexmedetomidine in adults’ burns wound dressing-A randomized double-blind cross over study. Burns. 2013;39:1150–56. doi:10.1016/j.burns.2013.02.012.
   PubMed Web of Science ®Google Scholar
• Nooh N, Sheta SA, Abdullah WA, Abdelhalim AA. Intranasal atomized dexmedetomidine for sedation during third molar extraction. Int J Oral Maxillofac Surg. 2013;42:57–862. doi:10.1016/j.ijom.2013.02.003.
   Web of Science ®Google Scholar
• Fishman M, Tirado C, Alam D, Gullo K, Clinch T, Gorodetzky CW. Safety and efficacy of lofexidine for medically managed opioid withdrawal: a randomized controlled clinical trial. J Addict Med. 2019;13:169–76. doi:10.1097/ADM.0000000000000474.
   PubMed Web of Science ®Google Scholar
• Gish EC, Miller JL, Honey BL, Johnson PN. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010;44:343–51. doi:10.1345/aph.1M347.
   PubMed Web of Science ®Google Scholar
• Rehman SU, Maqsood MH, Bajwa H, Tameez U, Din A, Malik MN. Clinical efficacy and safety profile of lofexidine hydrochloride in treating opioid withdrawal symptoms: a review of literature. Cureus. 2019;11:e4827. doi:10.7759/cureus.4827.
   PubMed Web of Science ®Google Scholar
• Kohli U, Pandharipande P, Muszkat M, Sofowora GG, Friedman EA, Scheinin M, Wood AJ, Ely EW, Tyndale RF, Choi L, et al. CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol. 2012;68:937–42. doi:10.1007/s00228-011-1208-z.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Health Alert Network. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities; 2015. [accessed 18 Nov 2019]. https://emergency.cdc.gov/han/han00384.asp
   Google Scholar
• Martinez S, Jones JD, Brandt L, Campbell AN, Abbott R, Comer SD. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. Am J Addic. 2020;30:65–71. doi:10.1111/ajad.13092.
   PubMed Web of Science ®Google Scholar
• Comer SD, Cahill CM. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49–57. doi:10.1016/j.neubiorev.2018.12.005.
   PubMed Web of Science ®Google Scholar
• Luba RL. As secondary analysis examining Fentanyl’s impact on opioid withdrawal symptoms and exploring the role of body weight in Fentanyl clearance. College on Problems of Drug Dependence Annual Meeting; 2002 June 15; Minneapolis, MN.
   Google Scholar